Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate PK with Fluconazole
NCT02275975Phase 1Completed
- Start
- Jul 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of pemafibrate in dyslipidemia (2 arms). Primary endpoint: Maximum concentration at 72 hours. Started Jul 2014; status: completed.
02
Drugs
pemafibrate
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02275975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275975.